dopamine transporter

Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson’s Disease With Neuroprotective Potential.

Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson’s Disease with Neuroprotective Potential.

Rambam Maimonides Med J. 2010 Jul; 1(1): e0003
Finberg JP

Rasagiline (Azilect) is a highly selective and potent propargylamine inhibitor of monoamine… Continue reading →

Imaging Addiction: D2 Receptors and Dopamine Signaling in the Striatum as Biomarkers for Impulsivity.

Imaging addiction: D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity.

Neuropharmacology. 2013 Jul 9;
Trifilieff P, Martinez D

Dependence to drugs of abuse is closely associated with impulsivity, or the propensity to choose a lower,… Continue reading →

Transdermal Buprenorphine, Opioid Rotation to Sublingual Buprenorphine, and the Avoidance of Precipitated Withdrawal: A Review of the Literature and Demonstration in Three Chronic Pain Patients Treated With Butrans.

Transdermal Buprenorphine, Opioid Rotation to Sublingual Buprenorphine, and the Avoidance of Precipitated Withdrawal: A Review of the Literature and Demonstration in Three Chronic Pain Patients Treated With Butrans.

Am J Ther. 2013 Jul 10;
Kornfeld H, Reetz H

Buprenorphine… Continue reading →

Obesity Alters the Gustatory Perception of Lipids in the Mouse: Plausible Involvement of the Lingual CD36.

Obesity alters the gustatory perception of lipids in the mouse: plausible involvement of the lingual CD36.

J Lipid Res. 2013 Jul 9;
Chevrot M, Bernard A, Ancel D, Buttet M, Martin C, Abdoul-Azize S, Merlin JF, Poirier H, Niot… Continue reading →

Integrating the Human Sciences to Evolve Effective Policies.

Integrating the Human Sciences to Evolve Effective Policies.

J Econ Behav Organ. 2013 Jun 1; 90(Suppl): S152-S162
Biglan A, Cody C

This paper describes an evolutionary perspective on human development and wellbeing and contrasts it with the model of… Continue reading →

Open Label Trial of Naltrexone Implants: Measuring Blood Serum Levels of Naltrexone.

Open label trial of naltrexone implants: measuring blood serum levels of naltrexone.

Subst Abuse. 2013; 7: 75-84
Colquhoun RM

The usefulness of oral naltrexone has been limited by compliance. Sub-cutaneous implants would seem to offer a solution to this… Continue reading →

?CaMKII Autophosphorylation Controls the Establishment of Alcohol-Induced Conditioned Place Preference in Mice.

?CaMKII autophosphorylation controls the establishment of alcohol-induced conditioned place preference in mice.

Behav Brain Res. 2013 May 31;
Easton AC, Lucchesi W, Mizuno K, Fernandes C, Schumann G, Giese KP, Müller CP

The autophosphorylation of alpha Ca(2+)/calmodulin dependent protein… Continue reading →

MicroRNAs and Drug Addiction.

MicroRNAs and Drug Addiction.

Front Genet. 2013; 4: 43
Bali P, Kenny PJ

Drug addiction is considered a disorder of neuroplasticity in brain reward and cognition systems resulting from aberrant activation of gene expression programs in response to prolonged… Continue reading →

Deleuze and the Theory of Addiction.

Deleuze and the theory of addiction.

J Psychoactive Drugs. 2013 Jan-Mar; 45(1): 57-67
Oksanen A

This theoretical article presents and applies the theories of the French philosopher Gilles Deleuze. The article takes as its starting point the observation that… Continue reading →

GET73 Increases Rat Extracellular Hippocampal CA1 GABA Levels Through a Possible Involvement of Local mGlu5 Receptor.

GET73 increases rat extracellular hippocampal CA1 GABA levels through a possible involvement of local mGlu5 receptor.

Synapse. 2013 Apr 8;
Beggiato S, O’Connor WT, Tomasini MC, Antonelli T, Loche A, Tanganelli S, Cacciaglia R, Ferraro L

N-[(4-trifluoromethyl) benzyl] 4-methoxybutyramide… Continue reading →